The Food and Drug Administration's 2004 antidepressant warning was followed by decreases in antidepressant prescribing for youth. This was due to declines in all types of depression treatment, not just the intended changes in antidepressant prescribing patterns. Little is known about how these patterns varied by race/ethnicity. Interrupted time series analyses measured changes due to the warning in levels and trends, by race/ethnicity, of three outcomes: antidepressant prescription fills, depression treatment visits, and incident fluoxetine prescription fills.
INTRODUCTION
The Food and Drug Administration (FDA) issued a boxed warning (BW) for antidepressant medications in 2004 to address the risk of suicidal ideation in younger users after a series of related advisories and media reports. After the warning, significant declines were observed in pediatric antidepressant use (Busch et al., 2010; Olfson, Marcus, & Druss, 2008) . These declines were driven predominantly by declines in antidepressant prescribing for White youth and not racial/ethnic minority youth (DePetris, , suggesting that the BW did not influence antidepressant prescribing for minority youth and White youth equally. Treatment of pediatric depression also declined during this time period (Libby et al., 2007) , suggesting that the BW may have had a chilling effect on provider willingness to treat pediatric depression. It is not known whether changes in pediatric depression treatment also differed by race/ethnicity following the BW. Disparities research in this area can help policy makers and clinicians anticipate how future medication warnings will affect medication and officebased treatment in vulnerable populations. Both major depressive disorder (MDD) (Merikangas et al., 2010) and suicidal ideation (Evans, Hawton, Rodham, & Deeks, 2005) are common across all groups of youth, and so appropriate prescribing of antidepressants across racial/ethnic groups, and for particularly vulnerable groups such as those insured by Medicaid, remains a serious public health concern (Cummings, & Druss, 2011) .
FDA warnings for other classes of psychotropic medications have been associated with differential prescribing effects across racial/ethnic groups. One example is the sharper decline in olanzapine prescription fills among White patients as compared to Hispanic patients after a 2003 FDA warning on the use of certain antipsychotic medications (Dusetzina et al., 2012; Dusetzina, Cook, Busch, Alexander, & Huskamp, 2013) . Systematic reviews of FDA risk communications have observed decreases in antidepressant use and "spillover" decreases among older age groups not included in the warning, though subgroup analysis of racial/ethnic differences are not available (Dusetzina et al., 2012) . As the FDA continues to issue antidepressant warnings, some with unintended consequences (e.g., unintended increases in hospitalizations after a 2011 FDA communication on recommended citalopram dosages; Rector, Adabag, Cunningham, Nelson, & Dieperink, 2016) , it is necessary to identify the impact of FDA warnings on treatment patterns for vulnerable patient groups.
Though the FDA warning included all antidepressants, fluoxetine was the only selective serotonin reuptake inhibitor (SSRI) that had an FDA indication for treatment of pediatric depression through 2009 (Hirsch, Katz, 2003) in part due to evidence for best outcomes in this population (Whittington et al., 2004) . Though tricyclic antidepressants were also FDA approved for treating depression in children, these medications have a worse safety profile than SSRIs (Geller, Reising, Leonard, Riddle, & Walsh, 1999) . Examining the warning's impact on fluoxetine prescribing overall and by racial/ethnic group represents the chance to examine whether there was a shift toward an antidepressant with the best evidence at the time, and whether this shift occurred equally across racial/ethnic groups.
Using Medicaid data from 2002 to 2009, we examined how the BW influenced trends in racial/ethnic disparities in antidepressant prescription fills for youth, and to what extent changes in treatment of pediatric depression explain these trends. Incident prescription fills of fluoxetine were also specifically assessed to disentangle whether the warning shifted new prescriptions toward the only SSRI with formal FDA indication for treatment of pediatric depression. We studied youth insured by Medicaid because this group is more likely to include racial/ethnic minority youth (Saloner, Carson, & Cook, 2014) and to use antidepressants relative to privately insured youth both before and after the FDA warning (DePetris, & Cook, 2013) . Medicaid data offer a detailed record of healthcare visits, diagnoses, and prescription drug used over time and across settings for vulnerable youth (Crystal, Akincigil, Bilder, & Walkup, 2007) , thus making these data appropriate to a disparities analysis of antidepressant use. Medicaid coverage for youth in the four states studied in this paper is prevalent; with mean estimates in 2013 of approximately 42% (Kaiser Family Foundation).
We tested three hypotheses. First, we hypothesized that antidepressant prescription fills and depression treatment among Whites, compared to Black and Latino youth, would show the greatest decrease in rate and the greatest decline in trend (slope) in an interrupted time series (ITS) analysis. Second, we hypothesized that the larger declines in antidepressant prescription fills among White youth were driven by larger declines in depression treatment visits for White youth compared to other racial/ethnic groups. Third, we hypothesized that White youth would have an increased rate of incident prescription fills of fluoxetine compared to Black and Latino youth. To conduct an ITS analysis, individual data were aggregated by month and by race/ethnicity for a sample of 249 observations (three race/ethnicity × 96 months minus 13 months "phase-in," described 
METHODS

Study sample
Dependent variables
The three dependent variables of interest were rates of any antidepressant prescription fill, any treatment visit for pediatric depression, and incident prescription fill of fluoxetine. Antidepressant prescribing was defined as any antidepressant prescription fill in a given calendar month. This was determined by matching therapeutic class and medication name in pharmacy claims data to the National Drug Code directory (U.S. FDA, 2014). Any treatment visit for pediatric depression in a given month was defined by having a diagnosis of MDD or a related psychiatric disorder (ICD-9-CM codes 296.xx-300.xx or 311.xx) on a medical claim assigned by a clinician for treatment of outpatient, inpatient, or long-term care settings. 
Data analysis
We used an ITS approach, estimating ordinary least square (OLS) regression models to compute predicted rates and slopes before and after the warning in October 2004 for antidepressant prescription fills, any treatment visit for pediatric depression, and incident prescribing of fluoxetine by month and race/ethnicity. ITS is a strong quasiexperimental research design (Penfold, & Zhang, 2013 ) that controls for baseline rates and slopes in outcomes before the implementation of the policy being studied (Wagner, Soumerai, Zhang, & Ross-Degnan, 2002) . By examining changes in outcomes in large populations before and after a specific time period, ITS differences out contextual variables whose effect does not vary greatly over time, such as state residence or proportion of Medicaid-insured racial/ethnic groups in each state. Therefore, the regression in this analysis controlled only for racial/ethnic group, the interaction between race/ethnicity group and post-BW indicator, the interaction between race/ethnicity and pre-BW ITS models adjusted for baseline trends and included a binary indicator to estimate the immediate level change in outcomes after the BW as well as a term indicating the slope change after the warnings. Coefficients for indicators of Black race and Latino ethnicity, and interactions between race/ethnicity and rate and slope indicators, were also included. Using linear combinations of these coefficients, we calculated the predicted racial/ethnic disparities in rates and slopes of antidepressant prescription fills, any treatment of pediatric depression, and incident fluoxetine prescription fills, and tested for their significance.
Results are presented graphically to visually inspect the time series for differences before and after the BW in slope and rate (Wagner et al., 2002) . The analysis tested for serial correlation between time periods using the Durbin-Watson statistic and adjusted for significant firstorder autoregressive parameters to control for correlation between consecutive months (Wagner et al., 2002) . Models were adjusted for month-fixed effects regardless of the year to control for variation in antidepressant prescribing related to seasonality.
Finally, we assessed changes in racial/ethnic group rates and slopes of antidepressant prescribing conditional on having a pediatric depression treatment visit. Results from this model, viewed alongside results from the model of any pediatric depression visit, provide evidence on whether overall declines in antidepressant prescribing were due to declines in depression visits, or declines in provider prescriptions among those with a visit. Table 1 describes unadjusted outcomes, demographics, and clinical characteristics of the study sample. Temporary Assistance for Needy Families was the most common reason for Medicaid eligibility across all three groups. On average, White youth were more likely to be diagnosed with MDD (0.8%) than Black (0.5%) and Latino (0.3%) youth, and had over twice the frequency of filling an antidepressant prescription in a given month (5.9%) compared to Black (2.6%) and Latino (1.6%) youth. Table 2 ). The decrease among White youth was greater than those for Blacks and Latinos (P < .001 for both comparisons). Regarding the change in slopes, rates of prescription fills before the BW (slope before warning) were increasing across all three racial/ethnic groups, with a significantly larger positive slope among White youth. Following the BW, the slopes reversed to negative for White and Black youth and flattened among Latino youth, with a significantly greater negative shift in slope among White youth (P < .001 for both comparisons). White youth therefore experienced the biggest drop in rate and biggest slope decline of antidepressant prescription fills post-BW compared to Black and Latino youth. Rate trajectories diverged after the warning: White youth showed declines in any pediatric depression treatment visits (P < .001, see Table A1 ); Black youth showed slightly increasing rates of any pediatric depression treatment over time (P < .01); and Latino youth had steady rates of depression treatment. In summary, slopes were affected most markedly among White youth, who showed the largest downward shift in slope (P < .001 compared to Black, and P < .05 compared to Latino). Figure 3 shows disparities in rates and slopes of incident fluoxetine prescription fills across the three patient groups among those patients who had no mental health visit, nor any antidepressant prescription fill, in the previous 90 days (see Table A2 for full results). The rates youth. This was higher than rates for Black and Latino youth with any depressive disorder (2,633/10,000 and 2,488/10,000, respectively).
RESULTS
Antidepressant prescription fills
Treatment visits for pediatric depressive disorder
Incident prescription fills of fluoxetine
Antidepressant prescription fills among those with a depressive disorder
The rate of antidepressant prescribing dropped from October 2003
to October 2004 at similar levels and then continued to decline for all three groups, most among Black youth (Table A3) .
DISCUSSION
This disparities analysis shows a greater immediate drop and greater decline in antidepressant prescription fills among White youth following the BW when compared to Black and Latino youth. One interpretation of these results is that information in the BW may have diffused less rapidly to the prescribers and/or caregivers of minority patients, Black youth seemed relatively protected from this chilling effect, since their treatment visits increased slightly in the wake of the warning (Fig. 2) as did incident fluoxetine prescriptions compared to Whites (Fig. 3 ). This appears to be a rare example where depression visits increased following the antidepressant warning, as was recommended in the BW. From a disparities perspective, these outcomes are encouraging. Our current analysis is not able to determine whether those increased visits followed new prescriptions or dose changes. Further qualitative research could explore how providers and families of underserved youth heard and reacted to the warning.
Across all groups, incident fluoxetine prescription fills jumped and continued increasing even as antidepressant prescription fills declined, suggesting that provider responses shifted toward an FDA-indicated medication for this population. Our hypothesis that White youth would see greater incident fluoxetine prescription fills was not supported. In the months after the BW, providers across all racial/ethnic groups prescribed an evidence-based option for incident medication treatments of depression, suggesting the BW may have been associated with beneficial effects on dissemination of best practices when new prescriptions were being recommended.
The mechanism underlying the differential decrease in antidepressant prescription fills post-BW cannot be identified in these data.
However, our findings of a differential impact of the warning by race/ethnicity convey the importance of the role of patient and caregiver decision making, since they are ultimately responsible for filling prescriptions. Prescribing clinicians in Nebraska reported that 22% of caregivers refused antidepressants for their children after the FDA warning, as did 9% of pediatric patients (Bhatia et al., 2008) . Our results may partly be explained by White caregivers and patients being more likely to decline depression treatment.
Another explanation for racial/ethnic differences in prescription fills may be found in the declining rates of depression treatment visits after the warning. In our results, not only did antidepressant prescription fill rates drop more sharply for White youth than Black and Latino youth following the warning, so did visits for pediatric depression treatment. These findings can be viewed in light of evidence that suicide rates may have increased after the BW in relation to the decrease in pediatric depression treatment (Libby et al., 2007; Lu et al., 2014) .
Minority youth, in particular Black youth, may have been somewhat protected from these negative consequences.
Given that lifetime prevalence rates are equal or even greater for Black and Latino youth as compared to Whites (Merikangas et al., 2010) , it does appear that depression management remains inadequate for racial/ethnic minorities. Both pre-and post-BW, minority youth attended fewer visits, providing less opportunity to discuss and act on FDA medication warnings. Other literature shows that minority youth were less likely to receive depression treatment from mental health specialists (Bach, Pham, Schrag, Tate, & Hargraves, 2004; Cummings, & Druss, 2011) , and specialists were far less likely than family medicine clinicians and pediatricians to discontinue depression treatment post-BW (0.8, 3.9, and 11.5%, respectively) (Bhatia et al., 2008) . Further research should clarify how BWs affect both family preferences for treatment discipline (e.g., pursuing specialty mental health care) and antidepressant preferences. and advocacy by change agents may complement the FDA's efforts to address the "information asymmetries" that deprive patients and providers of medication information (Busch et al., 2010) . This is especially true in child psychopharmacology, which has a much smaller evidence base available to guide drug-specific policy recommendations (Hammad, Neyarapally, Iyasu, Staffa, & Dal Pan, 2013) .
These data should be interpreted in the context of limitations associated with research using Medicaid data. Prescription fills in claims data are not equal to medication adherence, since caregivers may later decide not to give the medication and patients may decide to not take it. Therefore, the rates of prescription fills in our findings represent an "upper-bound estimate" of true antidepressant use (Crystal et al., 2007) . It is also not possible to determine whether decreases in antidepressant prescription fills were the result of changes in provider or caregiver/patient behavior, although the question of how comparative effectiveness evidence diffuses to both groups remains of interest. Our findings reflect the results of a decision-making process that involves, to varying degrees, prescriber, caregiver, and youth. Although large sample sizes of all three racial/ethnic groups were analyzed, concerns have been raised regarding the accuracy of ethnicity reporting for these groups in claims data (Gomez, Kelsey, Glaser, Lee, & Sidney, 2005) , suggesting that some minorities may have been misclassified as 
CONCLUSION
